Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Amgen Inc. (NASDAQ:AMGN) is one of the best pharma stocks to invest in now. Amgen Inc. (NASDAQ:AMGN) announced on March 28 that Repatha® lowered the risk of first major adverse cardiovascular events ...
Amgen’s cholesterol drug Repatha proved effective at lowering the risk of heart attacks, strokes and death in patients with heart disease in a recent clinical trial, reports Reuters. When reporting ...
Repatha is the most extensively studied PCSK9 inhibitor, with clinical and real-world evidence across diverse populations and CV risk profiles. 7 The clinical benefits and safety of Repatha have been ...
Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally. 3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results